Compare · ABT vs PRPH
ABT vs PRPH
Side-by-side comparison of Abbott Laboratories (ABT) and ProPhase Labs Inc. (PRPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and PRPH operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $154.45B, about 1381.4x PRPH ($111.8M).
- Over the past year, ABT is down 33.0% and PRPH is down 89.1% - ABT leads by 56.0 points.
- ABT has been more active in the news (7 items in the past 4 weeks vs 1 for PRPH).
- ABT has more recent analyst coverage (25 ratings vs 3 for PRPH).
- Company
- Abbott Laboratories
- ProPhase Labs Inc.
- Price
- $89.72+1.18%
- $0.36-18.27%
- Market cap
- $154.45B
- $111.8M
- 1M return
- +6.26%
- +0.00%
- 1Y return
- -33.02%
- -89.07%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 7
- 1
- Recent ratings
- 25
- 3
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
ProPhase Labs Inc.
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter (OTC) consumer healthcare products and dietary supplements in the United States. It offers a range of OTC dietary supplements, including Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support product; and Super ProstaFlow+ a supplement to support prostate and urinary health under the TK Supplements brand. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; and offers SARS-CoV-2 (COVID-19) and COVID-19 viral mutation PCR tests through saliva and nasal swab methods, as well as other respiratory pathogen panel testing services, including Influenza A and B, and others. It serves consumer products companies, as well as large national chain, regional, specialty, and local retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was incorporated in 1989 and is headquartered in Garden City, New York.
Latest ABT
- Abbott declares 410th consecutive quarterly dividend
- New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
- SEC Form 10-Q filed by Abbott Laboratories
Latest PRPH
- SEC Form 10-K filed by ProPhase Labs Inc.
- SEC Form NT 10-Q filed by ProPhase Labs Inc.
- ProPhase Labs Reports Year-End 2025 Results, Highlights Accelerating Settlement Activity and Investment-Ready Crown Medical Collections Platform
- SEC Form NT 10-K filed by ProPhase Labs Inc.
- ProPhase Labs Provides Business Update Highlighting Advancing Crown Medical Collections Activity
- ProPhase Labs Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- ProPhase Labs Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- ProPhase Labs Initiates Potential Sale or Strategic Partnership of BE-Smart™ and Advances Crown Medical Collections Initiative
- Join ProPhase Labs' Exclusive Live Investor Webinar and Q&A Session on February 3rd
- ProPhase Labs Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits